Norethisterone acetate transdermal - Pierre Fabre

Drug Profile

Norethisterone acetate transdermal - Pierre Fabre

Latest Information Update: 15 May 2008

Price : $50

At a glance

  • Originator Amarin Corporation
  • Class Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2008 Discontinued - Preregistration for Menopausal syndrome in France (Transdermal)
  • 17 Jun 2003 No development reported - Preregistration for Menopausal syndrome in France (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top